In fact, loss-of-function mechanisms may play as serious a role as any other factor contributing to ALS pathology, so it is therefore unrealistic to expect that simply eliminating mutant SOD1 will be adequate in human gene therapy for ALS [comprehensively reviewed by Kim et al. (2020)]. Here, SOD1 is linked to amyotrophic lateral sclerosis.